Sequence: CRGDKGPDC
| Experiment Id | EXP001784 |
|---|---|
| Paper | Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC- |
| Peptide | CC9 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | CC9 content ~8.23 wt% on polymer for PC-CC9-10% feed (supporting info); free CC9 not added |
| Rna Concentration | miR-34a 0.15 µM per well (6-well) for qRT-PCR; 0.15 µM FAM-siRNA for uptake (2 µg per well) at N/P 25 |
| Mixing Ratio | N/P = 30 (polymer N to miRNA phosphate) |
| Formulation Format | PC-CC9/miRNA polyplex (covalent peptide-conjugated polymer) |
| Formulation Components | PEI600-β-cyclodextrin (PC) covalently conjugated with CC9 (optimal: PC-CC9-10% feed) complexed with miR-34a at N/P 30 |
| Size Nm | 225.00 |
| Zeta Mv | 8.60 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | PANC-1 (pancreatic cancer) (primary in vitro efficacy); BxPC-3 also tested; 293T as normal control |
| Animal Model | |
| Administration Route | |
| Output Type | In vitro functional effects: miR-34a upregulation (qRT-PCR), cell cycle arrest, apoptosis, migration inhibition, target gene downregulation |
| Output Value | miR-34a expression substantially increased vs PBS/free miR-34a; apoptosis ~41% (Annexin V/PI) for PC-CC9/miR-34a; reduced E2F3/Bcl-2/c-myc/cyclin D1 |
| Output Units | |
| Output Notes | Targeting effect specific to tumor cells (uptake enhancement not observed in 293T). Low cytotoxicity by MTT. |
| Toxicity Notes | Low cytotoxicity in PANC-1/BxPC-3/293T (MTT, supporting info). |
| Curation Notes |